Patients with osteoarthritis-related pain were shown to benefit from cognitive behavioral therapy for insomnia (CBT-I) via telephone, in which the treatment significantly improved sleep and fatigue after 12 months, with pain temporarily relieved as well.
Cognitive behavioral therapy for insomnia (CBT-I) was shown to improve sleep and fatigue among patients with osteoarthritis-related pain, according to study findings published this week in JAMA Internal Medicine.
Insomnia is a common comorbidity in older adults alongside other chronic conditions. Notably, more than half of patients with osteoarthritis, which affects 50% of older adults, report symptoms of disturbed sleep.
“Insomnia and chronic pain have reciprocal effects, each initiating, maintaining, and exacerbating one another,” noted the study authors
Recently, CBT-I has emerged as an effective therapeutic intervention for people with comorbid conditions and was recommended for use in recent clinical practice guidelines issued by the American Academy of Sleep Medicine. More noteworthy amid the pandemic, CBT-I delivered via telemedicine was found to be noninferior to in-person delivery in managing severity of insomnia and improving daytime functioning.
As the first large randomized trial to assess CBT-I delivered via telephone among older adults with comorbid moderate to severe insomnia and chronic osteoarthritis pain, the Osteoarthritis and Therapy for Sleep study compared the efficacy of the remote therapy with education-only control (EOC) in 327 participants 60 years and older from Kaiser Permanente Washington (mean [SD] age, 70.2 [6.8] years; 244 [74.6%] women).
The study was conducted from September 2016 to December 2018, with participants undergoing six 20- to 30-minute telephone sessions (n = 163) or EOC (n = 164) over 8 weeks. Participants were double screened 3 weeks apart for moderate to severe insomnia and osteoarthritis pain symptoms, and were blindly assessed for the primary outcome of Insomnia Severity Index (ISI) score at baseline, 2 months posttreatment, and at 12-month follow-up.
In addition to the ISI, secondary outcomes included pain (Brief Pain Inventory-short form), depression (8-item Patient Health Questionnaire), and fatigue (Flinders Fatigue Scale).
“Participants submitted daily diaries and received group-specific educational materials,” explained study authors. “The CBT-I instruction included sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and homework. The EOC group received information about sleep and osteoarthritis.”
Among the 282 participants who provided follow-up ISI data, total 2-month posttreatment ISI scores exhibited a significant adjusted mean between-group difference of −3.5 points between the CBT-I group and the EOC group (95% CI, −4.4 to −2.6 points; P < .001), which was sustained at 12-month follow-up (adjusted mean difference, −3.0 points; 95% CI, −4.1 to −2.0 points; P < .001).
Additionally, at 12-month follow-up, 56.3% of participants receiving CBT-I remained in remission (ISI score ≤ 7), compared with 25.8% of those receiving EOC.
Secondary outcome measures indicated:
“Telephone CBT-I was effective in improving sleep, fatigue, and, to a lesser degree, pain among older adults with comorbid insomnia and osteoarthritis pain in a large statewide health plan,” concluded study authors. “Results support provision of telephone CBT-I as an accessible, individualized, effective, and scalable insomnia treatment.”
Reference
McCurry SM, Zhu W, Korff MV, et al. Effect of telephone cognitive behavioral therapy for insomnia in older adults with osteoarthritis pain. JAMA Intern Med. Published online February 22, 2021. doi:10.1001/jamainternmed.2020.9049
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More